Introduction {#sec0005}
============

Pyoderma gangrenosum (PG) is an inflammatory disease, most commonly characterized by painful cutaneous ulcers with irregular, violaceous borders located on the lower limbs. It is frequently associated with inflammatory bowel diseases (IBD), inflammatory arthropathies, and hematologic malignancies.[@bib0735], [@bib0740] The worldwide incidence is estimated to be around two to three cases per 100,000 habitants per year,[@bib0745] but this might be underestimated due to lack of a diagnostic gold standard. Pathogenesis is not well understood, but studies have suggested an abnormal immune response in patients with genetic predisposition, hence PG is classified within the spectrum of neutrophilic and auto-inflammatory syndromes.[@bib0750], [@bib0755]

Other pathologic conditions in the clinical differential diagnosis -- including infections, vasculitis/vasculopathy, and neoplastic disorders -- should be ruled out with the assistance of laboratory testing, as well as histopathologic and microbiological studies.[@bib0760] First-line treatment includes systemic corticosteroids and cyclosporine. Second-line and third-line therapeutic options comprise immunosuppressive, immunomodulatory, and biologic agents.[@bib0765] The present study aimed to review the literature in order to recommend the best approach when facing patients with PG in Latin America (LA).

Methods {#sec0010}
=======

A systematic review was performed of the case-reports and case-series studies of PG from countries in LA published in MEDLINE (PubMed) and LILACS from inception to October 2018. The search strategies are available in [Table 1](#tbl0005){ref-type="table"}.Table 1Search strategyTable 1DatabasePubMed: (<https://www.ncbi.nlm.nih.gov/pubmed/>) Date: October 23rd, 2018.ResultsStrategy\#1Search (chile OR brazil OR peru OR brasil OR colombia OR mexico OR ecuador OR venezuela OR uruguay OR cuba OR puerto rico OR costa rica OR latin america OR argentina)702779\#2Search Pyoderma Gangrenosum\[tiab\]2853\#3Search (\#1 AND \#2)61DatabaseLILACS (<http://pesquisa.bvsalud.org/portal/>) Date: October 23rd, 2018.ResultsStrategy\#1(tw:(pyoderma gangrenosum)) AND (instance:"regional") AND (db:("LILACS"))141

Epidemiology {#sec0015}
------------

PG is considered a rare disease of with estimated prevalence of two to three cases per 100,000 people and an adjusted incidence rate of 0.63 per 100,000 person-years. Risk of death is three times higher than general controls.[@bib0770] It tends to have a slight predominance for females.[@bib0770], [@bib0775] Differences in comorbid conditions and differential diagnoses to consider vary significantly depending on geographic regions and local disease prevalence. Reports from LA are scarce and mostly consist of case reports or case series.[@bib0780]

Pathogenesis {#sec0020}
------------

Neutrophilic dysfunction has been implicated in the pathogenesis of PG.[@bib0775] In addition, pathergy, which is defined as a nonspecific increase of neutrophil activity reaction, is present in other neutrophilic dermatoses (*e.g.*, Behcet\'s disease and Sweet\'s syndrome) but it has been described in at least 30% of patients.[@bib0785], [@bib0790] Neutrophilic dysfunction shares the same pro-inflammatory effectors found in auto-inflammatory syndromes. Both are characterized by an over-activated innate immune system leading to the increased assembly of inflammasomes.[@bib0740] Inflammasomes are responsible for the activation of the caspase 1, a protease that cleaves the pro-interleukin IL-1β into functionally active IL-1β. The overproduction of IL-1β triggers the release of several pro-inflammatory cytokines and chemokines, inducing the recruitment and activation of neutrophils and subsequent neutrophil-mediated inflammation.[@bib0755] IL-17 appears to be crucial in the recruitment of neutrophils in auto-inflammation and acts synergistically with tumor necrosis factor (TNF).[@bib0795], [@bib0800] Finally, IL-1β, IL-17, and TNF-α activate and increase the production of matrix metalloproteinases (MMPs), which are overexpressed in the inflammatory infiltrate of PG, causing an inflammatory insult and the consequent destruction of the involved tissue.[@bib0740], [@bib0755]

In conclusion, PG is the result of innate immune system over-activation *via* inflammasomes, coupled with the activation of the adaptive immune system, triggered by an external insult (*e.g.*, pathergy) and/or a possible internal trigger in a genetically predisposed individual.[@bib0805]

Histopathologic findings {#sec0025}
------------------------

PG has non-specific histopathologic findings. Presence of perifollicular inflammation, edema, and neutrophilic inflammation are the initial features seen in untreated and expanding PG lesions. Polymorphonuclear leukocyte infiltration can lead to abscess formation and necrosis of the tissue with mixed inflammatory infiltrate. Additional findings may include giant cells, secondary thrombosis of small- and medium-sized vessels, and hemorrhage. Secondary leukocytoclastic vasculitis is present in around 40% of cases. Direct immunofluorescence also yields non-specific findings such as deposition of IgM, C3, and fibrin in the papillary and reticular dermal vessels. Due to the non-specific findings, skin biopsies are more useful to rule out other causes of ulceration that may present with similar clinical findings, such as infections, vasculitis, vasculopathies, or malignancies.[@bib0790], [@bib0810], [@bib0815], [@bib0820]

Clinical features {#sec0030}
-----------------

PG is classified into four clinical subtypes: classic (ulcerative) ([Figure 1](#fig0005){ref-type="fig"}, [Figure 2](#fig0010){ref-type="fig"}), bullous, pustular, and vegetative ([Figure 3](#fig0015){ref-type="fig"}, [Figure 4](#fig0020){ref-type="fig"}). Ulcerative or classic PG often starts as an inflammatory erythematous violaceous pustule of a few millimeters in size, which enlarges forming an ulceration that gradually increases both in size and depth. The ulcer discharges a purulent and hemorrhagic exudate, easily detectable by applying pressure on its border. The purulent and malodorous exudate can be attributable to a bacterial colonization or to an actual superinfection. The border is well demarcated, elevated, and slowly progressive, with a violaceous color. An erythematous, edematous, and infiltrated halo extends up to 2cm from the border of the ulcer.[@bib0740], [@bib0755], [@bib0825] The lesion is usually solitary, but multiple ulcers can occur; they are typically painful, ranging from a few millimeters to 30cm or more, localized mostly in extensor surface of the legs, but they can affect any anatomic site. They may be deep enough to expose tendons, fasciae, and muscles.[@bib0755], [@bib0830] Lesions start in healthy skin and may be provoked by trauma (pathergy). Therefore, postoperative PG ([Figure 5](#fig0025){ref-type="fig"}, [Figure 6](#fig0030){ref-type="fig"}), peristomal PG, and worsening of lesions after sharp or surgical debridement frequently occur.[@bib0835] The ulcer can propagate rapidly, showing a serpentine configuration.[@bib0745], [@bib0825] PG has been classically associated with inflammatory colitis (IBD and diverticulitis), hematological malignancies (myelodysplastic syndrome, monoclonal gammopathy, chronic myeloid leukemia, *etc.*), autoimmune inflammatory disease (seronegative polyarthritis, rheumatoid arthritis), and solid tumors (prostate and colon adenocarcinoma).[@bib0750], [@bib0770] Finally, sterile neutrophilic infiltrates have been found to affect internal organs supporting the concept of PG being a systemic disease.[@bib0840]Figure 1Classic or ulcerative pyoderma gangrenosum.Figure 2Classic or ulcerative pyoderma gangrenosum.Figure 3Vegetative or verrucous pyoderma gangrenosum in a patient with Behcet\'s disease.Figure 4Vegetative or verrucous pyoderma gangrenosum in a patient with Behcet\'s disease.Figure 5Pyoderma gangrenosum after abdominoplasty.Figure 6Multiple pyoderma gangrenosum ulcers at the sites of sclerotherapy injections.

Results {#sec0035}
=======

In LA, 118 studies were found from 1981 to 2018, with 232 cases of PG. Brazil was the country with the largest report of case-series, with 96 (41.4%) cases of PG. The next highest total was from Argentina, which has 69 (29.7%) reported cases of PG, followed by Chile and Mexico, which have a similar number of reported cases, with 21 (9.1%) and 17 (7.3%), respectively. In addition, the results of the systematic review show that ulcerative PG was the most frequent type of PG reported, and that the others had similar prevalence. Bullous, vegetative (granulomatous), and pustular PG were reported in nine (3.9%), eight (3.5%), and five (2.1%) cases. The rest of PG cases did not report the subtype ([Table 2](#tbl0010){ref-type="table"}).Table 2Prevalence of Latin American pyoderma gangrenosum cases reported in the literatureTable 2Total (*n*)%UlcerativeGranulomatousPustularBullousBrazil9641.3876313Argentina6929.7457223Bolivia10.431‒‒‒Chile219.0520‒1‒Colombia166.9014‒‒‒Costa Rica10.431‒‒‒Cuba20.8611‒‒Mexico177.3351‒‒Paraguay10.43‒‒‒1Peru52.162‒12Venezuela31.2921‒‒TOTAL232100179859%100‒77.163.452.163.88

In addition, the systematic review found that there was a high prevalence of PG cases associated with comorbidities. Overall, 149 (64.5%) and 37 (16%) of the patients included in the analysis had PG associated to a condition or surgery, respectively. In the rest of PG patients, no other conditions or disease associations were reported. IBD was the most frequent conditions associated (53/149, 35.6%), then ulcerative colitis (UC) (32/149, 21.5%) and Crohn\'s disease (10/149, 6.7%). Other inflammatory diseases were also frequent (54/149, 36.2%); among them, rheumatoid arthritis (RA) (17/149, 11.4%), antiphospholipid syndrome (APS) (15/149, 10.1%), systemic erythematous lupus (4/149, 2.7%), and Takayasu\'s arteritis (4/149, 2.7%) were reported. Several malignances were reported in association with PG (19/149, 12.8%), in particular hematologic malignancies (14/149, 9.4%) and solid-organ malignancies (5/149, 3.4%). Other conditions were also reported (23/149, 15.4%), including the presence of pulmonary nodules (5/149, 3.4%) of unknown etiology. In regard to surgical procedures, reduction mammoplasty (9/149, 6.0%), laparotomy (6/149, 4.0%), and skin grafting (4/149, 2.7%) were the more frequent triggers of PG. It is important to mention that due to the limited information in the reports and the scarce number of PG cases, only descriptive statistical analysis was performed ([Table 3](#tbl0015){ref-type="table"}).Table 3Prevalence of the conditions associated with pyoderma gangrenosum reported in the Latin American literatureTable 3Condition*n*%*IBD* No specified117.4 UC3221.5 CD106.7 Subtotal5335.6  *Malignancy* Hematologic malignancy149.4 Solid-organ malignancy53.4 Subtotal1912.8  *Inflammatory* Antiphospholipid syndrome1510.1 Rheumatoid arthritis1711.4 Lupus erythematosus42.7 Takayasu\'s arteritis42.7 Other149.4 Subtotal5436.2  *Other conditions* Pulmonary nodules53.4 Cocaine consumption21.3 Diverticular disease21.3 Pregnancy21.3 Other128.1 Subtotal2315.4 Total14964.5[a](#tblfn0005){ref-type="table-fn"}  *Secondary to surgery* Reduction mammoplasty922.5 Laparotomy615.0 Abdominoplasty410.0 Skin grafts410.0 Total surgery3716.0[b](#tblfn0010){ref-type="table-fn"}[^1][^2]

Thus, the systematic review of PG case-series from LA helped to elucidate the main associated conditions. In [Table 4](#tbl0020){ref-type="table"}, all the studies where PG was reported to be associated with clinical or surgical conditions are listed.Table 4Conditions associated with pyoderma gangrenosum (PG) reported in the Latin American literatureTable 4*n*AuthorYearCountryNumber of patientsClinical typeAssociated diseaseSecondary to surgery or drugs1Corti et al.[@bib1025]1981Argentina1UlcerativeCrohn\'s diseaseNo2Della-Giovanna et al.[@bib1030]1991Brazil4UlcerativeTwo patients with ulcerative colitis, one with pregnancyNo3Moreno et al.[@bib1035]1994Argentina2UlcerativeTwo patients with rheumatoid arthritisNo4Vignale et al.[@bib1040]1996Argentina4UlcerativeThree patients with Crohn\'s disease, two with seronegative arthritis, and one with ulcerative colitisNo5Saraceno et al.[@bib1045]2002Argentina6UlcerativeOne patient with myelodysplastic syndrome, one with rheumatoid arthritis, one with hemophagocytic syndrome and hepatitis CNo6Plaza[@bib1050]2004Argentina1UlcerativeRheumatoid arthritisNo7Simon et al.[@bib1055]2005Argentina1UlcerativeUlcerative colitisPeristomal after total colectomy8Vazquez et al.[@bib1060]2009Argentina1UlcerativeChronic osteomyelitisKnee prosthesis replacement9Sommerfleck et al.[@bib1065]2014Argentina1Not reportedUlcerative colitisNo10Achenbach et al.[@bib1070]2014Argentina1UlcerativeCrohn\'s diseaseSulfasalazine11Curmona et al.[@bib1075]2014Argentina2UlcerativeOne patient with metastatic ovarian cancerAbdominal tumor resection12Pereyra et al.[@bib1080]2014Argentina1UlcerativeRenal transplantNo13Fassi et al.[@bib1085]2015Argentina1UlcerativeRheumatoid arthritis and ulcerative colitisNo14Silva-Feistner et al.[@bib1090]2015Argentina1UlcerativeNoneCesarean15Galimberti et al.[@bib1095]2016Argentina1UlcerativeUlcerative colitisNo16Vacas et al.[@bib0735]2017Argentina27UlcerativeTen patients with IBD, seven with hematologic malignances, five with rheumatoid or seronegative arthritis, and one with cocaine consumptionNo2Bullous2Pustular17Vega et al.[@bib1100]2018Argentina1UlcerativeRetroperitoneal fibrosisExploratory mid-laparotomy18Vacas et al.[@bib1105]2018Argentina1BullousAcute and chronic myeloid leukemiaNo19Pires et al.[@bib1110]1987Brazil1UlcerativeChronic hepatitisNo20Lana et al.[@bib1115]1990Brazil1UlcerativeMultiple sclerosisNo21Pessato et al.[@bib1120]1996Brazil9Not reportedFive patients with comorbiditiesNo22Souza et al.[@bib1125]1999Brazil11Predominantly ulcerativeOne patient with ulcerative colitis, one with rheumatoid arthritis, one with Grave\'s disease, one with diabetes mellitusNo23Cabral et al.[@bib1130]2004Brazil4UlcerativeFour patients with ulcerative colitis, one with additional primary sclerosing cholangitis, one with seronegative arthritisNo24Martinez et al.[@bib1135]2005Brazil1UlcerativeUlcerative colitisNo25Costa et al.[@bib1140]2005Brazil1UlcerativeRheumatoid ArthritisNo26Fraga et al.[@bib1145]2006Brazil1Superficial granulomatousPsoriasisNo27Coltro et al.[@bib1150]2006Brazil1Ulcerative in donor siteNoneSkin graft for varicose ulcers28Batista et al.[@bib1155]2006Brazil1BullousMyelodysplastic syndromeNo29Meyer et al.[@bib1160]2006Brazil1UlcerativeCrohn\'s diseaseInfraumbilical median laparotomy30Franca et al.[@bib1165]2006Brazil1UlcerativeGastric adenocarcinomaNo31Burkieviecz et al.[@bib1170]2007Brazil1UlcerativeSystemic lupus erythematosus/antiphospholipid syndromeNo32Barbato et al.[@bib1175]2008Brazil13UlcerativeTwo patients with Crohn\'s disease, two with diabetes, two with collagenosis, one with leukemia.No2Superficial granulomatous1Bullous33Tinoco et al.[@bib1180]2008Brazil1UlcerativeAcneIsotretinoin34Dornelas et al.[@bib1185]2008Brazil1UlcerativeNoneReduction mammoplasty and abdominoplasty35Bonamigo et al.[@bib1190]2008Brazil1UlcerativeNoneBreast implant with silicone prosthesis and facial surgery36Coelho et al.[@bib1195]2009Brazil2UlcerativeInflammatory arthritis/splenomegalyNo37Berbert et al.[@bib1200]2009Brazil1Superficial granulomatousNoneDonor site after skin grafting for burns.38Furtado et al.[@bib1205]2010Brazil1UlcerativeNoneReduction mammoplasty and abdominoplasty39Avelar et al.[@bib1210]2011Brazil1UlcerativeBreast cancerBreast quadrantectomy and radiotherapy40Fonseca et al.[@bib1215]2011Brazil1BullousUlcerative colitisNo41Grillo et al.[@bib1220]2012Brazil1UlcerativeNoneReduction mammoplasty42Maia et al.[@bib1225]2012Brazil1UlcerativeCocaine useNo43Cunha et al.[@bib1230]2012Brazil1UlcerativeNoneLaparoscopy44Bittencourt et al.[@bib1235]2012Brazil1UlcerativePulmonary nodulesNo45Andrade et al.[@bib1240]2012Brazil1UlcerativeInflammatory bowel diseaseNo46Carvalho et al.[@bib1245]2013Brazil1UlcerativeSplenic and renal impairmentNo47Kruger et al.[@bib1250]2013Brazil1UlcerativeUlcerative colitisNo48Soares et al.[@bib1255]2013Brazil1UlcerativeNoneReduction mammoplasty and abdominoplasty49Beber et al.[@bib1260]2014Brazil1UlcerativeRheumatoid arthritisNo50Marchiori et al.[@bib1265]2014Brazil1UlcerativePulmonary nodulesNo51Rosseto et al.[@bib1270]2015Brazil1UlcerativeNoneAbdominoplasty52de Souza et al.[@bib1275]2015Brazil1UlcerativeMyelodysplastic syndromeNo53Sempertegui et al.[@bib1280]2015Brazil1UlcerativeBreast cancerBreast quadrantectomy and radiotherapy54Soncini et al.[@bib1285]2016Brazil1UlcerativeNoneAugmentation mastopexy55Dantas et al.[@bib1005]2017Brazil1UlcerativeAutoimmune hepatitisNo56Freitas et al.[@bib1290]2017Brazil1UlcerativeIliac vein compression syndromeNo57Gabe et al.[@bib1295]2018Brazil1UlcerativePyogenic arthritisNo58Bittencourt et al.[@bib1300]2018Brazil1UlcerativeMultiple myelomaAutologous stem cell transplantation and then laparoscopic cholecystectomy59Clemente et al.[@bib1305]2018Brazil2UlcerativeTwo patients with atypical Takayasu\'s arteritisNo60Perez et al.[@bib1310]2001Chile2UlcerativeNoneCesarean61Lopez de Maturana et al.[@bib1000]2001Chile3UlcerativeTwo patients with diverticular disease, one patient with Crohn\'s disease, one patient with rheumatoid arthritisNo1Pustular62Hevia et al.[@bib1315]2004Chile1UlcerativeUlcerative colitisPeristomal after total colectomy63Eulufi et al.[@bib1320]2006Chile3UlcerativeNoneTwo patients after skin graft, one patient after reduction mammoplasty64Calderon et al.[@bib1325]2011Chile1UlcerativeUlcerative colitisNo65Fernandez-Castillo et al.[@bib1330]2012Chile1UlcerativeWegener granulomatosis/chronic kidney diseaseArteriovenous fistula66Gosch et al.[@bib1335]2012Chile1UlcerativeNoneReduction mammoplasty67Melo and Fernandez [@bib1340]2013Chile1UlcerativeNoneFoot and ankle surgery68Calderon et al.[@bib1345]2013Chile3UlcerativeNoneAfter reduction mammoplasty69Bannura et al.[@bib1350]2014Chile1UlcerativeUlcerative colitisLaparotomy/ileostomy70Erlij et al.[@bib1355]2018Chile1UlcerativeErythema induratum and large B-cell non-Hodgkin\'s lymphomaNo71Penaloza et al.[@bib1360]1988Colombia1UlcerativeUlcerative colitisNo72Restrepo et al.[@bib1365]2006Colombia2UlcerativeTwo patients with ulcerative colitisNo73Jaime-Lopez et al.[@bib1370]2009Colombia1UlcerativeUlcerative colitisInfliximab74Cañas et al.[@bib1375]2010Colombia7UlcerativeSeven patients with antiphospholipid syndromeNo75Cadavid et al.[@bib1380]2012Colombia1UlcerativeUlcerative colitisNone76Severiche et al.[@bib1385]2014Colombia1UlcerativeBreast phyllodes tumor (paraneoplastic)No77Acon-Ramirez et al.[@bib1390]2017Costa Rica1UlcerativeRheumatoid arthritisNo78Moreira-Preciado et al.[@bib1395]2001Cuba1Superficial granulomatousRenal failureNo79Hernandez-Urra et al.[@bib1400]2010Cuba1UlcerativeUlcerative colitisNo80Zonana-Nacach et al.[@bib1405]1994Mexico2Not reportedTwo patients with rheumatoid arthritisNo81Reynoso-von Dratein et al.[@bib1020]1997Mexico9Not reportedThree patients with rheumatoid arthritis and two patients with systemic lupus erythematosusNo82Chacek et al.[@bib1410]1998Mexico1UlcerativeInferior cava vein syndrome due to thrombosis and antiphospholipid syndromeNo83Muñiz-Gonzalez et al.[@bib1415]2007Mexico1UlcerativeUlcerative colitis, diverticular diseaseNo84Contreras-Ruiz et al.[@bib1420]2008Mexico1UlcerativeRheumatoid arthritisNo85Barrera-Vargas et al.[@bib1425]2015Mexico2UlcerativeTwo patients with pulmonary nodules and Takayasu\'s arteritisNo86Contreras-Verduzco et al.[@bib1430]2018Mexico1Superficial granulomatousPulmonary nodules and nodular scleritisNo87Real-Delor et al.[@bib1435]2011Paraguay1BullousUlcerative colitisNo88Dominguez et al.[@bib1440]2009Peru1PustularUlcerative colitisNo89Carrillo-Nanez et al.[@bib1445]2014Peru1BullousUlcerative colitisNo90Deza-Araujo et al.[@bib1450]2014Peru1UlcerativeSystemic lupus erythematosusNo91Fermin et al.[@bib1455]1989Venezuela2UlcerativeOne patient with ulcerative colitisNo92Valecillos et al.[@bib1460]1998Venezuela1Superficial granulomatousPregnancyNo

Infectious PG-mimickers to be considered in LA and/or from LA {#sec0040}
-------------------------------------------------------------

In general, ulcerative entities resembling PG fall into one of six disease categories: (a) primary deep cutaneous infections (*e.g.*, sporotrichosis, cutaneous tuberculosis, leishmaniasis, *etc.*) ([Figure 7](#fig0035){ref-type="fig"}, [Figure 8](#fig0040){ref-type="fig"}); (b) vascular occlusive or venous disease (*e.g.*, APS, venous stasis ulceration, *etc*.); (c) vasculitis (*e.g.*, Wegener\'s granulomatosis, polyarteritis nodosa, *etc.*); (d) malignant processes involving the skin (*e.g*., angiocentric T-cell lymphoma, anaplastic large-cell T-cell lymphoma, *etc*.); (e) drug-induced or exogenous tissue injury (factitial disorder, loxoscelism, *etc.*); and (f) other inflammatory disorders (cutaneous Crohn\'s disease, ulcerative necrobiosis lipoidica, *etc.*). However, in LA, the most common differential diagnoses include deep cutaneous infections, vascular occlusive disease, and metabolic disorders.[@bib0845] It is crucial for the management of PG in this region to rule out infection, as immunosuppressive medications used to treat PG may be contraindicated in these patients.[@bib0850] Depending on the specific region, infectious ulcers can be caused by *Leishmania* parasites, atypical *Mycobacterium* species, deep fungal infections (sporotrichosis, chromoblastomycosis and, mycetoma), myasis, and cutaneous amebiasis.[@bib0745]Figure 7Cutaneous leishmaniasis lesions can mimic classic pyoderma gangrenosum lesions.Figure 8Cutaneous leishmaniasis lesions can mimic classic pyoderma gangrenosum lesions.

Cutaneous leishmaniasis (CL) is a common skin disease in developing countries, such as Brazil and Peru.[@bib0855] Lesions may start as a papule or a nodule that develops into an ulcer with or without a scar ([Figure 7](#fig0035){ref-type="fig"}, [Figure 8](#fig0040){ref-type="fig"}). They are usually painless, but when painful, secondary infection is generally present. The initial diagnosis of CL is based on the clinical presentation and the patient\'s history of visiting an endemic area. Diagnostic work up includes multiple components in order to provide the highest likelihood of confirmation. Biopsy specimens should be obtained for impression smears, histopathologic slides with hematoxylin and eosin, Giemsa stain and special stains for other microbes, culture, and polymerase chain reaction (PCR) analysis if diagnosis is challenging.[@bib0860]

Ulcerating cutaneous lesions can be caused by mycobacterial infections including *Mycobacterium ulcerans*, *M. marinum*, and *M. tuberculosis. M. ulcerans* is the third most common agent of mycobacterial disease (after tuberculosis and leprosy) and the most common mycobacterium causing cutaneous ulceration.[@bib0865] Buruli ulcers, which are caused by *M. ulcerans*, are endemic in foci in West Africa and have been reported as an imported disease in countries of LA such as Peru, Brazil, Guiana, and Mexico.[@bib0870] Microscopy and PCR are used for routine diagnosis, while culture is less useful given time requirements and lack of species specificity.[@bib0875] Treatment is generally surgical, although a combination of rifampicin and streptomycin may be effective in the early stage.

Cutaneous tuberculosis (CTB) is an infection caused by *M. tuberculosis* complex, *M. bovis*, and in immunocompromised hosts, by bacillus Calmette-Guérin (BCG) vaccination.[@bib0880] An increase in its incidence has been described in several countries of LA in recent years, especially in urban centers and regions with high prevalence of human immunodeficiency virus (HIV) infection. Lupus vulgaris is a form of CTB that initiates as smoldering papular or tuberous lesions and progresses to plaques with necrosis and ulceration, with or without cicatricial deformities and mutilations.[@bib0885] Diagnostic approaches to CTB include skin biopsy with acid fast bacilli stain and culture, as well as PCR amplification testing of biopsy tissue.[@bib0890]

Sporotrichosis is one of the most common deep mycoses; it may be accompanied by ulceration.[@bib0895] Most cases of sporotrichosis are currently being reported in South and Central America, with recent outbreaks transmitted by cats.[@bib0900] The primary cutaneous lesions may appear as papular, nodular, or pustular lesions that develop into either a superficial ulcer or a verrucous plaque. During progression, the lymphocutaneous form displays multiple subcutaneous nodules that are formed along the course of locally draining lymphatics (sporotrichoid spread). In contrast, the localized form shows no lymphatic spread and is characterized by indurated or verrucous plaques and occasional ulcers.[@bib0905], [@bib0910] Diagnosis of sporotrichosis is primarily clinical due to its distinguished presentation, but in difficult cases, culture is the gold standard.[@bib0915]Sporotrichosis is treated with systemic itraconazole.[@bib0920]

Mycetoma is a chronic subcutaneous fungal infection caused by inoculation *via* organic matter such as splinters or thorns. Given the ubiquitous nature of causative fungi, there may be a genetic predisposition to developing the disease.[@bib0925] In South America, the most common pathogens are *Trematosphaeria grisea*, *Madurella mycetomatis*, and *Scedosporium apiospermum*. The clinical manifestations of mycetoma include painless slow growing subcutaneous nodules, which may evolve into necrotic abscesses with sinus tracts. Lesions are most commonly located on exposed areas, especially the lower extremities. The expression of black granules and debris from the lesions is highly suggestive of fungal mycetoma.[@bib0930] Diagnostic work up includes tissue microscopy using potassium hydroxide, as well as deep tissue biopsies for culture on Sabouraud dextrose agar kept at both room temperature and 37 °C. As fungal cultures can take several weeks, histopathologic evaluation may expedite the diagnosis but may not aid in identifying the causative species.

Furuncular myiasis is most commonly caused by larval tissue penetration by *Dermatobia hominis*, the botfly, and *Cordylobia anthropophaga*, the tumbu fly. Lesions slowly evolve into periodically painful nodules. They may present with multiple nodules containing larvae, and removal of the larvae typically relieves symptoms.

Cutaneous amebiasis is a rare extracutaneous manifestation of *Entamoeba histolytica* infection. It can occur independently through direct inoculation or along with other tissue involvement. There is predilection of the disease in the perineal region due to direct inoculation from stool, leading to ulcerations, but lesions can be present anywhere on the body.[@bib0935] Notable clinical features include one or more painful and malodorous ulcers with a necrotic base.[@bib0940] The edges of the lesions are often raised and red in color. Progression of the ulcers is often rapid, with destruction in all planes.[@bib0940] Confirmation of the diagnosis can be made with identification of the pathogen on tissue biopsy of the ulcer. Cytologic smears may also be useful in identifying the trophozoites.[@bib0940]

Chromoblastomycosis infection is causes by fungal spore implantation into the skin at sites of trauma. The fungus is ubiquitous in the soil and vegetation and therefore is highly associated with trauma occurring in the outdoors.[@bib0945], [@bib0950] This inoculation leads to a chronic granulomatous reaction. The infection initially begins as an inflamed macule, which evolves into a papule and eventually develops into one of several morphologic subtypes, including nodular, verrucous, tumorous, cicatricial, or plaque types.[@bib0955] Disease progression is very slow and is usually limited to the skin and subcutaneous tissue. Due to the mechanism of inoculation, it most commonly occurs on the lower extremities. One rare complication in chronic lesions is squamous cell carcinoma transformation.[@bib0950], [@bib0955] Diagnosis is made by identifying muriform cells on microscopy.[@bib0950], [@bib0955], [@bib0960], [@bib0965], [@bib0970] Samples can be obtained *via* scrapings, tape preparation, wet mounts, tissue biopsy, or culture. Treatment is dependent on the stage at diagnosis; early lesions can be treated effectively with surgery or cryotherapy. Pharmacologic treatment options are systemic antifungals for refractory or extensive disease.[@bib0950], [@bib0965], [@bib0975]

Treatment of PG in LA {#sec0045}
---------------------

There is no gold standard therapy for PG, but treatment should be guided by extension and depth of the ulcer, associated systemic diseases, the patient\'s performance status, and availability of medications.[@bib0745], [@bib0980] Topical therapy is the first choice for small lesions in the early stages (papules, pustules, nodules, or superficial ulcers). It includes dressings, topical immunomodulators, and intralesional corticosteroid injections.[@bib0985] A report from Chile showed an excellent and rapid respond to cyclosporin 5%, clobetasol 0.05%, and gentamycin 0.2% ointment applied twice daily, after 18 weeks.[@bib0990]

In patients with severe forms of PG, or with rapid expansion and resistance to topical treatment, systemic therapy is the treatment of choice. Corticosteroids are the first line drugs in the acute phase and should be initiated at high doses (1--2 mg/kg).[@bib0745], [@bib0995] A steroid-sparing drug should be used in the initial phases to minimize long-term steroid toxicity and side effects. Agents including dapsone, sulfasalazine, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, and biologics may be employed.[@bib0740], [@bib0995]

In LA, systemic corticosteroids are, by far, the most frequent first-line therapy. In a cohort of patients with PG, systemic corticosteroids were administered to 87% of patients (*n* = 27), at a dose-range of 1--1.5 mg/kg/day, for two to 14 months.[@bib0735] In another cohort, these drugs were initiated in 81.8% of the patients (*n* = 9); after 60 months, only two patients had been recurrence free, while the others had multiple recurrences, treated with sulfamethoxazole and trimethoprim, minocycline, topical corticosteroids, and cyclophosphamide.[@bib1000] In addition, corticosteroids and local treatment were preferred when PG was associated with autoimmune diseases, such as autoimmune hepatitis.[@bib1005]

Cyclosporine is less frequently used as a first-line therapy due to its side effects. Cyclosporine monotherapy induces a rapid remission of the disease at a dose of 3--5 mg/kg/day after a few weeks of treatment and complete resolution of the lesion after one to three months, but long-term therapy might be problematic.[@bib0745] In one report from LA, it was used in 13% (*n* = 4) of the patients, for one to six months, with a dose of 1.5--3 mg/kg/day, with no relapses after four years of treatment.[@bib0735]

Experience with methotrexate in LA is scarce, and it is generally used as a steroid-sparing drug in severe or refractory disease.[@bib1010] However, a case report from Chile showed a remarkable response with intralesional methotrexate. After 40 days of oral prednisolone, followed by eight weeks of 10 mg weekly intramuscular methotrexate, the PG ulcers failed to improve. After seven injections of methotrexate (25 mg/week) administered intralesionally in the erythematous border of the ulcers, almost 90% of the ulcer was healed.[@bib1015]

In Mexico, an open-label trial assessed intravenous bolus cyclophosphamide in a dose of 500 mg/m^2^ of body surface area monthly for a total of three or six doses in nine patients with PG. Seven patients had complete remission, one experienced failure, one had partial remission, and three had relapses after three and twelve months.[@bib1020] However, rare but severe side effects, such as infertility, hemorrhagic cystitis, and secondary tumors, might limit its use.[@bib0745]

Dapsone and sulfasalazine were reported only in two patients with PG in Chile.[@bib1000] However, recurrence occurred on multiple occasions and each patient was eventually transitioned to systemic steroids and cyclosporine.

For steroid-resistant PG, biological agents are now increasingly used in LA. TNF-α inhibitors are preferred due to availability and long-term safety data, but the high cost of these medications is still a limitation in this region.

Conclusion {#sec0050}
==========

Based on the current studies, PG in LA is still an under-reported disease and there is a lack of robust studies. The most frequent form of PG is the ulcerative subtype, which is most commonly associated with IBD. An accurate diagnosis in LA is even more challenging, as the prevalence of cutaneous infections that mimic all forms of PG is higher compared to developed countries. Being aware of the epidemiological variations of infectious diseases might provide clinical clues in the diagnosis of PG-like lesions, not only in people from these areas but also in immigrants and travelers. Treatment of PG is primarily with systemic corticosteroids; however, some positive outcomes have been reported with cyclosporine and methotrexate. In LA, biological therapy data is scarce and apparently reserved for severe forms of PG non-responsive to steroids due to high cost and limited access.
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[^1]: Total of patients with comorbidities/total of patients with PG × 100.

[^2]: Total of patients with PG secondary to surgery/total of patients with PG × 100.

    IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn\'s disease.
